CAMBRIDGE, Mass., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the 15th Annual BIO CEO & Investor Conference in New York City. Marc Beer, Chief Executive Officer of Aegerion, is scheduled to present on Tuesday, February 12, 2013 at 10:30 a.m. ET.
Aegerion will also participate in the Leerink Swann 2013 Global Healthcare Conference in New York City. Mark Fitzpatrick, Chief Financial Officer of Aegerion, is scheduled to present on Thursday, February 14, 2013 at 3:00 p.m. ET.
Both presentations will be webcast live and may be accessed for up to 14 days following the conference by visiting the "Investors" section of Aegerion's website, www.aegerion.com.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases. For more information about the company, please visit www.aegerion.com.
The Aegerion Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16441
CONTACT: Aegerion Pharmaceuticals, Inc.
Amanda Murphy
Manager, Investor Relations
857-242-5024
© 2024 Canjex Publishing Ltd. All rights reserved.